Acute myeloid leukemia
Conditions
Interventions
Aitologous stem cell transplantation:Aitologous stem cell transplantation
Favorable and intermediated-risk acute myeloid leu:Chemotherapy
High-risk acute myeloid leukemia:Allogeneic hemapoietic stem cell transplantation
High-risk acute myeloid leukemia:Chemotherapy
Sponsors
Hematology Peking University, People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: auto-HSCT 1. Patients with de novel AML(18-60 years) in favorable and intermediate-risk group; 2. Peripheral blood stem cell harvesting was started when included patients reached CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy and at least 2-4 courses of consolidation therapy including high-doses Ara-C; 3. ECOG=0,1; Allo-HSCT: 1. AML patients, (0.1% or >CR1; 2. Allogenic donor is available,
Exclusion criteria
Exclusion criteria: Aotu-HSCT: 1. Secondary AML, >60 years old; 2. AML 1.relapsed and refractory AML.2.ECOG >=2. 3. to reach CR1 with more than 2 courses of induction; 4. >CR1 or MRD level >0.1% (including RQ-PCR test ); 5. ECOG >=2. All0-HSCT: 1. relapsed and refractory AML; 2. ECOG >=2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| leukemia-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between MRD and relapse;Factors associated with prognose; | — |
Countries
China
Contacts
Public ContactKai-yan Liu
Outcome results
None listed